Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296263 · ClinicalTrials.gov registry record · NA
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
A NA study of Intra-axial Tumors and Extra-axial Tumors, sponsored by Hyperfine.
- Recruiting
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT07296263: Recruiting NA study of Intra-axial Tumors and Extra-axial Tumors, sponsored by Hyperfine.
NCT07296263 is a NA study of Intra-axial Tumors and Extra-axial Tumors that is actively recruiting participants, run by Hyperfine. The registered enrollment target is 85 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07296263, a NA study of Intra-axial Tumors and Extra-axial Tumors, is actively recruiting participants, sponsored by Hyperfine.
- RECRUITING
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions involving blood-brain barrier disruption. Each participant will undergo a pre-contrast pMRI scan, receive an intravenous GBCA injection, and then complete a post-contrast pMRI scan using the Swoop® Portable MR Imaging® System. Lesion visualization will be assessed by independent neuroradiologists using standardized scoring criteria. The study will be conducted across a minimum of three sites to ensure diversity in patient population, imaging environments, and GBCA types.
Conditions Studied
Interventions
- OTHER Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems
Study Locations (1)
Texas
- Texas Neurology - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What NCT07296263 shows while recruiting
NCT07296263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Intra-axial Tumors appearing as the primary indexed condition, and to 1 intervention - of which Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems is the first listed.
NCT07296263 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07296263 about?
NCT07296263 is a clinical study titled "Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems". This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions in...
What is the current status of trial NCT07296263?
This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2025-12-30. Estimated completion is 2026-06-01.
What conditions does trial NCT07296263 study?
This clinical trial studies the following conditions: Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions.
What interventions are being tested in trial NCT07296263?
The interventions under investigation include: Evaluation of Gadolinium Based Contrast Agents (GBCA) for Portable MR Imaging Systems (OTHER).
Who is sponsoring clinical trial NCT07296263?
This trial is sponsored by Hyperfine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07296263 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07296263's enrollment target sits among peer trials
85 980th of 2000 higher than 1,018 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI